Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TGM2 | P21980 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929347 | 0.89 | CYP3A4 (0.36) | MAPTALDH1A1CYP3A4CYP3A5 | |
| SCHEMBL277025 | 0.88 | MDM4 (0.43) | MAPTRAB9AMDM2GAACYP1A2 | |
| SCHEMBL274463 | 0.88 | MDM4 (0.43) | MAPTRAB9AMDM2GAACYP1A2 | |
| SCHEMBL699531 | 0.88 | MAPT (0.43) | MAPTMDM2 | |
| SCHEMBL274462 | 0.88 | MDM4 (0.43) | MAPTRAB9AMDM2GAACYP1A2 | |
| SCHEMBL275608 | 0.83 | PPARG (0.45) | MAPTALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL279165 | 0.83 | PPARG (0.45) | MAPTALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL275607 | 0.83 | PPARG (0.45) | MAPTALDH1A1KDM4ERAB9ASMN1; SMN2 | |
| SCHEMBL275659 | 0.81 | APP (0.35) | MAPTCYP3A4CYP3A5GAA | |
| SCHEMBL275658 | 0.81 | APP (0.35) | MAPTCYP3A4CYP3A5GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217051-B2 | Spiroindolinone derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-10 | — | — | US | disclosed |
| WO-2010094622-A1 | 3, 3' -SPIROINDOLINONE DERIVATIVES AS ANTICANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100210674-A1 | Spiroindolinone Derivatives | HOFFMANN-LA ROCHE INC. | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210674-A1 | Spiroindolinone Derivatives | RCC2, PKD1, SIK2 | MAPT 4074/4885ALDH1A1 258/4885CYP3A4 1989/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.